Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

NCT00948753 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Graft-versus-host Disease
Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Maraviroc 150 MG
DRUG: Maraviroc 300 mg
DRUG: Maraviroc 300 mg Phase II

Sponsor

Abramson Cancer Center at Penn Medicine